Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).

Nuria Romero-LaordenRebeca LozanoAnuradha JayaramFernando López-CamposMaria I SaezAlvaro MontesaAna Gutierrez-PecharomanRosa VillatoroBernardo HerreraRaquel CorreaAdriana RoseroMaría I PachecoTeresa GarcésYlenia CendónMa Paz NombelaFloortje Van de PollGala GrauLeticia RiveraPedro P LópezJuan-Jesús CruzDavid LorenteGerhardt AttardElena CastroDavid Olmos

Published in: British journal of cancer (2018)

In selected clinical stable mCRPC patients with limited disease progression on AA + P, a steroid switch from prednisone to dexamethasone can lead to PSA and radiological responses.

Keyphrases

phase ii
clinical trial
open label
high dose
low dose
prostate cancer
squamous cell carcinoma
small cell lung cancer
phase iii
placebo controlled